Biomatters to be Acquired by GraphPad to Form Industry Leading Life Sciences Software Platform
The strategic acquisition will enable the company to accelerate investment in innovation and solutions that further
serve and support its global customer base
AUCKLAND, New Zealand, Apr. 26, 2019 — New Zealand tech business Biomatters, a global leading provider of DNA data analysis solutions, announced today that it will be acquired by US company GraphPad, a leading provider of data analysis and visualization software for the life sciences industry. The acquisition creates
a life sciences software platform with technology and data analysis at the core of scientific research around the world.
Biomatters was incubated in Auckland’s Icehouse accelerator and launched with seed funding from the Ice Angels and NZ
Venture Investment Fund. Over the last decade the company has established its Geneious software as the premium brand for
DNA data analysis, used by leading academic institutions, and pharmaceutical and biotechnology companies worldwide.
Brett Ammundsen, CEO of Biomatters, is proud of the international success the company has achieved, and enthusiastic
about joining forces with GraphPad. “We have built a team with world-leading expertise and domain knowledge in applying
computation and graphical visualization to the challenges faced by life sciences researchers working with DNA data,” he
said. “The combination with GraphPad will further accelerate our mission to enable technologies based on molecular
biology to advance critical research in medicine, diagnostics, and agricultural and environmental science.”
“The acquisition of Biomatters is an exciting opportunity to better serve our customers and the scientific community,”
said Thomas Swalla, CEO of GraphPad. “There is a critical need for scientists and researchers to leverage technology in
a way that enhances—not impedes—innovation. As a unified company, we can invest further in these software solutions
allowing scientists to stay focused on advancing their research.”
In 2017, GraphPad received an investment from Insight Partners. Insight is a leading global venture capital and private equity firm investing in high-growth technology and software
companies.
“This is a strategic and exciting acquisition in the life sciences sector, which continues to see exponential growth in
the adoption of technology,” said Jeff Lieberman, Managing Director at Insight Partners. “By creating a platform that
delivers technology solutions to enable better data analysis across various aspects of the scientific workflow, we can
empower more customers to further scientific innovation. We will continue to invest in products and solutions to
complement the platform and further this mission.”
Following the acquisition, both companies will continue to operate and serve customers under their respective brands.
Visit www.graphpad.com and www.geneious.com for more information.
About Biomatters
Biomatters (www.geneious.com) empowers its customers with software that transforms biological data into knowledge and actionable insights across the
spectrum of biotechnology research and development, including drug discovery, protein engineering and advanced
comparative analysis of DNA, RNA and protein sequences. Geneious solutions are created from a deep understanding of
customer experience, and turn the difficult into the intuitive and easy. That is why Geneious is trusted by over 4,000
companies, universities and institutes all over the globe.
About GraphPad Software
For 25 years, GraphPad (www.graphpad.com) has been the leading provider of software developed exclusively for the international scientific community. GraphPad
Prism (https://www.graphpad.com/scientific-software/prism/), the company’s flagship product, is the preferred analysis and graphing solution purpose-built for scientific
research. Powerful, yet intuitive and helpful, Prism helps scientists discover and share the story in their data. Prism
has been trusted by more than 750,000 of the world’s leading scientists, from students to Nobel Prize winners, in
institutions and organizations including Stanford, Yale, Harvard, City of Hope, Center for Disease Control and
Prevention (CDC), NASA, Merck, Sanofi, and more.
ends